# Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

> **NCT04346914** · PHASE1 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 20 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide

## Key facts

- **NCT ID:** NCT04346914
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-08
- **Primary completion:** 2022-10-30
- **Final completion:** 2022-10-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346914, "Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04346914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*